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Abstract
A large number of artificial tears are currently available in the pharmaceutical 
market. Selecting the right drug for the patient remains a challenge for both the doc-
tor and the patient. Comparing the cytotoxicity of artificial tears is one of the criteria 
for the rational selection of a drug that promotes maximum clinical efficacy and 
a higher safety profile. It is known that cells grown in vitro retain many metabolic 
features of the parent host tissues and at the same time lack tissue and organ inter-
relations and regulatory effects of the nervous and endocrine systems and have very 
limited compensatory capabilities. These features of cell cultures provide an oppor-
tunity to investigate the interaction of chemical agents directly with the cell itself, to 
identify changes in cellular and subcellular structures that can be masked in whole-
organism settings. This study presents the results of assessing the cytotoxicity of tear 
substitutes, which demonstrate that these drugs can have a cytostatic effect in vitro 
and differ in their cytotoxic potential. In recent years, the problem of drug therapy of 
patients with dry eye syndrome has been attracting increasing attention of ophthal-
mologists, so screening the cytotoxicity of a wide range of tear substitutes using cell 
culture-based test systems can promote the rational selection of these drugs.
Keywords: cell cultures, cytotoxicity, artificial tear, preservatives, buffers,  
cornea, ocular surface epithelium
1. Introduction
Tear substitutes are widely used in ophthalmology today and are the first-line 
treatment of multifactorial causes that occur in various cases of irritation of the 
ocular surface, including dry eye syndrome (DES). Artificial tears contain the follow-
ing substances as active ingredients: sodium hyaluronate, carbomer, hydroxypropyl 
methylcellulose (HPMC), carmellose sodium, trehalose, as well as a combination 
of polyvinyl alcohol and povidone and HPMC together with dextran. In addition to 
the active ingredient, various preservatives are added to maintain the stability of the 
drops and suppress microorganism growth: benzalkonium chloride (BAC), cetrim-
ide, cetalkonium chloride, Polyquad®, polyhexanide, and also Oxide®, Purite®, and 
OcuPure®. Substances that increase the viscosity (prolongators) reduce the rate of 
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removal of the substance from the ocular surface. These include povidone, polyvinyl 
alcohol, glycerol, propylene glycol, gelatin, methylcellulose, dextran 70, and carboxy-
methylcellulose. The next component of eye drops is antioxidants; they prevent the 
decomposition of the active ingredient by atmospheric oxygen. The most commonly 
used antioxidants are EDTA, bisulfite, thiosulfate, and metabisulfite. Eye drops may 
contain buffer substances (systems), which allow maintaining the pH of the drug in 
the range of 6–8. This is necessary to ensure that the pH of the drops is similar to the 
normal acidity of a human tear (7.14–7.82). With such similarity, the active substances 
can easily penetrate the cornea into the anterior chamber of the eye, without causing 
discomfort during instillation. Examples of buffers are citrate, phosphate, borate, and 
Tris buffers. Another important component of eye drops is osmotic agents: propyl-
ene glycol, glycerol, dextrose, and dextran. These substances provide isotonicity of 
eye drops in relation to the tear film and maintain osmotic pressure at the level of 
305 mOsm/L. Isotonic solutions are better absorbed and well tolerated by the patient.
Thus, in addition to the main pharmaceutical ingredient, eye drops contain 
a number of excipients, some of which can have an adverse effect on the ocular 
surface, such as preservatives, buffer system components, and antioxidants.
The inclusion of preservatives in the composition of eye drops is necessary to 
maintain sterility and prevent their bacterial contamination. According to interna-
tional standards, the addition of preservatives is mandatory in the manufacture of 
multidose dosage forms for topical use.
The concentration of the latter in the composition of the eye drops is relatively 
low; however, the cumulative dose over the entire period of use, especially with their 
frequent and prolonged use, can be quite high. This is especially important to remem-
ber in the context of the development of side effects that can be caused by some of 
the excipients in eye drops, including artificial tears [1, 2]. The preservatives in the 
composition of eye drops can be divided into three main types: detergents, oxidiz-
ers, and ion buffer systems. Detergent-type preservatives have a broad spectrum of 
antimicrobial action, which makes them quite toxic for corneal and conjunctival cells 
[3]. Oxidizing preservatives are less toxic than detergents, while they are effective 
against bacteria even at low concentrations, which minimizes their adverse effects on 
conjunctival and corneal epithelial cells [4]. The ion buffer preservative with an anti-
bacterial and antifungal effect is similar to oxidizing agents in its mechanism of action 
[5]. It is less cytotoxic for the cells of the ocular surface than conventional preserva-
tives but is not yet included in the composition of tear substitutes currently [6].
In the United States, many comparative clinical studies have been conducted 
to assess the efficacy of tear substitutes. In the published report of the Dry Eye 
Workshop, it was noted that despite the fact that many tear substitutes improved 
the ocular surface condition, there was no reliable evidence that any of the drugs 
was superior to another, while the inflammation of the ocular surface could worsen 
in the presence of preservatives in their composition [7, 8].
Recently, studies of not only developed but already available drugs have been 
increasingly using in vitro test systems, among which models with monolayer cell 
cultures are the simplest and most accessible ones [9–11]. Cells grown in vitro 
retain many metabolic features of the parent host tissues and at the same time lack 
tissue and organ interrelations and regulatory effects of the nervous and endocrine 
systems and have very limited compensatory capabilities. These features of cell 
cultures provide an opportunity to investigate the interaction of chemical agents 
directly with the cell itself, to identify changes in cellular and subcellular structures 
that can be masked in whole-organism settings. It is known that cells affected by 
various biologically active substances can undergo changes in morphology, cell 
growth rate, time of death, and degree of disintegration; therefore, it is advisable 
for each dosage form to assess its effect on cell survival [12]. In toxicology studies, 
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various cell cultures are used. They differ in origin, belonging to a particular tissue 
type, sensitivity to various xenobiotics, as well as in their ability to proliferate. The 
selection of a test system in each case depends on the purposes and objectives of 
the study. To assess the safety of ophthalmic drugs, the most informative are test 
systems based on human eye tissue cells [13–18].
The purpose of this study was to comparatively analyze the cytotoxic effect of 21 
tear substitutes on human corneal epithelial cells in vitro.
2. Materials and methods
2.1 Test drugs
The study object was 11 tear substitutes with various systems of  
preservatives (Table 1) and buffer systems (Table 2), Systane® Ultra, Artelac® 
Balance, Optive®, Cationorm®, Vismed® Light, Blink® contacts, Stillavit®, 
Ophtolique®, Lacrisifi®, Hypromellose®-P, and Slezin®, and 7 preservative-free 
tear substitutes, Hylabak®, Thealoz®, Thealoz Duo®, Hylo-Comod®, Hyloparin-
Comod®, Hylosar-Comod®, and Hylomax-Comod® (Table 2).
2.2 Cell cultures used
Cells of the immortalized human corneal epithelial cell (HCE) line were used as 
a test system. This test system has a higher sensitivity to the action of tear substi-
tutes, compared with a test system based on the permanent human conjunctival cell 
line (Chang conjunctiva, clone 1-5c-4) [17].
2.3 Study design and methods
The effect of artificial tear eye drops on the viability of human corneal epithelial 
cells was studied in vitro during culturing the cells in Keratinocyte-SFM growth 
medium (Gibco, USA) containing the test drugs at a concentration of 10% of the 
Chemical glass of 
preservative
Name of preservative/antioxidant Trade name of tear substitute
Detergents BAC, EDTA Slezin®
BAC, EDTA Hypromellose®-P
BAC, EDTA Lacrisifi®
BAC, EDTA Ophtolique®
Polyhexanide, EDTA Vismed® Light
Polyquad® Systane® Ultra
Cetalkonium chloride Cationorm®
Oxidants Stabilized oxychloro complex
Purite® Optive®
OcuPure® Blink® contacts
Stabilized chlorite complex
Oxide® Artelac® Balance
Other EDTA Stillavit®
Table 1. 
The main groups of preservatives/oxidants in the tear substitutes.
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medium volume at 37°C in a CO2 incubator in an 5% CO2 atmosphere. Cells cultured 
under standard conditions without the addition of drugs were used as control cells. The 
concentration of tear substitutes for the experiment was selected on the data of clinical 
use of the test drugs and our own cytotoxicity studies of artificial tears on cell cultures 
[17]. Cell viability was assessed by their morphology and functional activity using 
phase-contrast microscopy (FCM) methods, MTT test, and xCELLigence system.
The morphology of the cells in the course of their culturing with the test 
drugs was evaluated using an inverted Nikon Eclipse TS100 microscope equipped 
with a camera. To evaluate the effect of tear substitutes on the metabolic activ-
ity of human corneal epithelial cells by MTT method, the cells were inoculated 
in 96-well plates in 200 μl of the growth medium containing the test drugs and 
cultured as usual for 2 days. After the culturing period, MTT test was performed. 
The absorbance of the solutions was measured using Fluorofot Charity analyzer 
(Russia) at a wavelength of 570 nm and a reference wavelength of 630 nm. 
Mathematical processing of the data was performed by variation statistics methods 
using Microsoft Excel 2007. Differences were considered significant at p < 0.05.
To evaluate the effect of tear substitutes on the adhesion and proliferative 
activity of corneal epithelial cells using xCELLigence system, 1 × 104 HCE cells 
were inoculated per well of the E-plate in 100 μl of the growth medium containing 
the test drugs. The plates were placed in the real-time cell analyzer dual purpose 
(RTCA-DP) (ACEA Biosciences), and adhesion and cell proliferation dynamics was 
monitored in real time for 24 h. The results were analyzed using RTCA Software 
1.2.1 (Roche). The change in impedance at microelectrodes due to cell attachment 
and spreading was expressed as Cell Index; the value of which is automatically 
calculated by the program: Cell Index = (RnRb)/t, where Rb is the initial impedance 
value in the well containing the cell growth medium only (negative control) and 
Rn is the impedance value at any time t in the well containing the test cells (positive 
control) in addition to the growth medium. The Cell Index thus reflects changes in 
the number of cells, the quality of cell attachment, and the morphology of the cells 
in the well, which may vary over time. The data were presented as the mean value 
(M) ± standard deviation, the significance of differences was calculated by the 
Mann-Whitney U-test, and differences were considered significant at p < 0.05.
3. Results and discussion
3.1 MTT test
The MTT test, commonly known as a screening method for measuring cell 
survival and included in most protocols of molecular biology and medicine [19], 
Buffer systems Tear substitutes
Citrate buffer (C) Hylo-Comod®, Hyloparin-Comod®, Hylomax-Comod®, Hylosar-Comod®
Phosphate buffer (P) Lacrisifi®
Borate buffer (B) Systane® Ultra, Blink® contacts, Slezin®
Tris buffer Cationorm®, Hylabak®, Thealoz®, Thealoz Duo®
Combination of buffers Optive® (B + C), Vismed® Light (P + C), Stillavit® (B + P)
No buffer Artelac® Balance, Ophtolique®
Table 2. 
Buffer systems in the study of tear substitutes.
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revealed differences in the effect of the test tear substitutes on the metabolic 
activity of the corneal epithelial cells. The results of the MTT test are presented as a 
histogram, where the viability of cells cultured in growth media with the addition 
of eye drops is expressed as a percentage relative to the control (Figure 1).
The MTT test showed that the tear substitutes containing preservatives from the 
group of detergents, especially BAC at various concentrations, have the greatest toxicity 
to corneal epithelial cells: Lacrisifi® (BAC 0.1 mg/mL), Slezin® (BAC 0.075 mg/
mL), Ophtolique® (BAC 0.1 mg/mL), Hypromellose®-P (BAC 0.1 mg/mL), and 
Cationorm® (cetalkonium chloride). Cell viability in the presence of these  
drugs was close to zero. The exceptions in this group were Vismed® Light (poly-
hexanide), which did not have a toxic effect at the studied concentration, and 
Systane® Ultra (Polyquad®), which had a moderate toxic effect. This was probably 
due to the fact that Vismed® Light contains the preservative polyhexanide, which 
is rarely included in the composition of tear substitutes. This preservative has a 
limited antifungal activity and no irritating effect on the human corneal epithelial 
cells [5]. The eye drops Systane® Ultra contain Polyquad® (polydronium chloride), 
which is a detergent-type preservative derived from BAC. It is unique in that bacte-
rial cells attract Polyquad®, while corneal epithelial cells tend to repel it. Despite 
the occurrence of some superficial epithelial lesions, it is better tolerated than other 
detergent-type preservative agents [20]. Extremely high toxicity to corneal epithe-
lial cells was also shown by the tear substitutes containing oxidants as preservatives: 
the stabilized oxychloro complex Optive® (Purite®) and the stabilized chlorite 
complex Artelac® Balance (Oxide®). The least toxic in this group was the Blink® 
tear substitute with OcuPure® as a preservative. It is thought that oxidative preser-
vatives have a mild cytotoxic effect and are well tolerated and safe [21]; however, 
it has been found that this group of preservatives can cause superficial punctate 
keratitis with prolonged use [22]. The group of tear substitutes consisting of only 
one drug (Stillavit®), which showed moderate toxicity compared to artificial tears 
with detergent- and oxidative-type preservatives, includes the antioxidant EDTA 
(sodium edetate). It is a chelating agent, which, while not being a true preservative, 
can increase the antimicrobial activity of the main disinfectant while reducing its 
concentration. It chelates the divalent cations of calcium and magnesium, mak-
ing the microorganisms more vulnerable to the preservative. Since EDTA chelates 
calcium and magnesium ions, it can also have a slight toxic effect on the corneal 
Figure 1. 
HCE viability histograms on day 3 of culturing in the medium with a concentration of the test drugs of 10% of 
the growth medium volume. The drugs were added to the growth medium at the time of inoculating the cells.
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cells, which need these ions for metabolism. Although EDTA does not generally 
have a pronounced toxic effect, there is evidence that patients with severe DES 
often complain of discomfort after using drugs containing EDTA [23].
The results of the study indicate the cytotoxic effect of tear substitutes with 
different chemical groups of preservatives on corneal epithelial cells. In scientific 
literature, this problem is currently covered quite objectively and completely. In 
addition to the active ingredient, preservatives, and some other excipients, tear sub-
stitutes contain various buffer systems (Table 2), which can have an adverse effect 
on corneal and conjunctival epithelial cells. Information on the comparative toxicity 
of the buffer systems included in the eye drops is almost not available. Nevertheless, 
separate reports present data on the occurrence of keratopathy and deposition of 
calcium hydroxyapatite in a transparent layer of the cornea, after using eye drops 
containing phosphate buffer [24, 25]. Phosphate-containing tear substitutes are 
widely used in the composition of ophthalmic dosage forms in EU countries, 
about a third of all buffered drugs contain phosphates as a buffer. The European 
Committee on Human Medicinal Products (CHMP) gives preference to the use of 
phosphate-containing drugs, reasoning that the risks do not exceed adverse reac-
tions that occur during their use, since the proportion of complications is less than 
1 case per 10,000 sold vials of tear substitutes. Calcification is a multifactorial com-
plication and can occur without the use of phosphate-containing drugs. Preference 
in selecting phosphate-containing tear substitutes should be given if it is consistent 
with the low risk of corneal calcification, especially in serious pathology, and on 
an individual case basis. It is not currently clear what phosphate concentration is 
critical for the onset of corneal calcification. Quite recently, preference has been 
given to borate buffers, which possess antimicrobial activity, showed good biocom-
patibility with the ocular surface both in vivo and in vitro and are considered safer 
[26, 27]. Tris buffers are also included in some dosage forms and have been found to 
be effective and low toxic [28].
As our studies have shown, the viability of human corneal epithelial cells 
depends, among other things, on the composition of the buffer system used in tear 
substitutes containing no preservatives. The lowest metabolic activity of cells in the 
study of a line of preservative-free tear substitutes was observed in the presence 
of Hylosar-Comod® containing citrate buffer together with dexpanthenol. The 
pronounced cytotoxic effect of Hylosar-Comod® on corneal epithelial cells can be 
due to the sensitivity of this test system to the combination of the drug ingredients. 
This question requires further investigation. A higher level of metabolism in cells 
was detected in the presence of three preservative-free tear substitutes containing 
citrate buffer (Hylomax-Comod®, Hyloparin-Comod®, and Hylo-Comod®). The 
average level of cell viability in this case ranged from 73 to 77%. The preservative-
free tear substitutes Hylabak®, Thealoz®, and Thealoz Duo® with Tris buffer 
showed no toxicity to corneal epithelial cells in our studies (Figure 1).
3.2 xCELLigence analysis
Based on the data obtained in the MTT test, eight products with various types of 
preservatives were selected from a wide range of tear substitutes for xCELLigence 
analysis: Artelac® and Blink® (oxidants), Ophtolique® and Systane® Ultra (deter-
gents), Stillavit® (EDTA), Hylo-Comod®, Thealoz Duo®, and Hylosar-Comod® 
(preservative free). These drugs within their groups showed varying degrees of 
toxicity to the metabolic activity of corneal epithelial cells. The xCELLigence real-
time cell analyzer (RTCA) technology is based on the use of microelectronic cell 
sensors integrated into the bottom of the wells of special culture plates (E-Plate). 
The resistance measured between the electrodes in a separate well depends on the 
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geometry of the electrode, the concentration of ions in the well, and whether the 
cells are attached to the electrodes. In the absence of cells, the electrode resistance 
is mainly determined by the ionic environment both at the electrode/solution 
interface and in the entire volume. The cells attached to the electrode surfaces act 
as insulators and thus change the local ionic medium at the electrode/solution 
interface, which will increase the resistance. Thus, the more cells spread on the 
electrodes, the higher the resistance of the electrodes. The presence of cells on the 
electrodes in the wells of the E-Plate affects the local state of the ionic environment, 
which leads to a change in the resistance on the electrodes. The Cell Index value is an 
indicator of electrical potential, which reflects the cell status. The Cell Index can be 
used for real-time monitoring of cell viability: their morphology, degree of adhe-
sion, cell growth (proliferation) dynamics, and other important parameters [12]. 
Continuous monitoring of the effect of tear substitutes on the HCE cell line in real 
time using the xCELLigence system revealed that the studied drugs at a concentra-
tion of 10% of the growth medium volume manifested varying degrees of toxicity 
to the cultured cells. In the course of monitoring, Cell Index-cell cultivation time 
plots were obtained, that made it possible to assess the cell viability by the degree of 
their spreading and proliferative activity (Figure 2).
As can be seen from the plots, of all the drugs tested using the xCELLigence 
system, the tear substitute Ophtolique® with BAC has the highest toxicity to the 
corneal epithelial cells (Figure 2B). The Cell Index equal to zero throughout the 
observation period indicates that cell adhesion has never occurred. In the presence 
of Artelac® Balance (Figure 2A) containing the preservative Oxide®, adhesion 
occurs within 1 h, but after 5 h, the cells begin to detach from the bottom of the 
wells, and after 10 h, no viable cells were detected. The xCELLigence analysis 
revealed an adverse effect of preservative-free Hylosar-Comod® containing citrate 
buffer with dexpanthenol on the cell culture (Figure 2D). This drug turned out to be 
the most toxic drug from the group of preservative-free tear substitutes; its cytotoxic 
effect was comparable to that of Blink® containing an oxidative-type preservative 
(Figure 2A). In the presence of these drugs, the cells could only adhere and spread. 
In the presence of Hylo-Comod® (Figure 2D) and Systane® Ultra (Figure 2B), the 
corneal epithelial cells adhered and spread, but their proliferation dynamics was low. 
Cell proliferation in the presence of Stillavit® (Figure 2C) was slightly lower than in 
the control, and the presence of Thealoz Duo® (Figure 2D) was comparable to the 
control, indicating that Stillavit® was moderately toxic and Thealoz Duo® did not 
exhibit toxicity at the given concentration to corneal epithelial cells.
Figure 2. 
Monitoring of the effect of tear substitutes with various types of preservatives ((A) oxidants, (B) detergents, 
(C) EDTA, (D) preservative-free drugs) on the viability of HCE cells in real time (proliferation curves). 
xCELLigence cell analysis.
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3.3 Observation of the cells morphology
The results of observation of the HCE cell morphology during their culturing in 
media containing 10% PCTs with various preservative systems are shown in Figure 3. 
In the pictures presented, the human corneal cells in the control are well spread, have 
a typical epithelium-like morphology, and have formed a confluent monolayer on 
cultivation day 3 (Figure 3E).
The morphology of the cells in the presence of the tear substitute Thealoz 
Duo® is comparable to the control. A slightly less dense monolayer than in the 
control is formed by the cells in the presence of Stillavit® in the growth medium. 
With Hylo-Comod®, the monolayer of cells is less dense than in the presence of 
Thealoz Duo® and Stillavit®. Most of the cells in the presence of the former drug 
are well spread, but their cytoplasm has a granular structure; a lot of unattached 
cells are observed. In the presence of the tear substitutes Blink® and Systane® 
Ultra, the monolayer is formed by about 50%; the cells have a vacuolated granu-
lar cytoplasm, which indicates their supressed state. With Hylosar-Comod®, 
a part of the cells have adhered, and intercellular contacts are found between 
them; in the presence of Artelac®, only single adherent cells are detected, and 
in the presence of Ophtolique®, no spread cells are found at all; most of the cells 
have a rounded shape. The cell structure is granular, with vacuoles; invagina-
tion of the cytoplasmic membrane is observed. Many cellular fragments are 
found in the growth medium. These observations suggest a launch of cell death 
processes. Thus, the results of the MTT test are consistent with the results of the 
xCELLigence cell analysis and the cell morphology analysis using phase-contrast 
microscopy methods.
Figure 3. 
Morphology of HCE cell line on the third day of culturing in a growth medium containing 10% of the test PCTs 
with various types of preservatives: oxidants (A, D), detergents (C, F), EDTA (B), and preservative-free drugs 
(G, H, I). Scale ruler 100 nm (20×). Phase-contrast microscopy.
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4. Conclusion
A large number of artificial tears are currently available in the pharmaceutical 
market. Selecting the right drug for the patient remains a challenge for both the 
doctor and the patient. This study presents the results of assessing the cytotoxic-
ity of tear substitutes, which demonstrate that these drugs can have a cytostatic 
effect in vitro and differ in their cytotoxic potential. Comparing the cytotoxicity of 
artificial tears is necessary for the rational selection of a drug that promotes maxi-
mum clinical efficacy and a higher safety profile. The tear substitutes Hylabak®, 
Thealoz®, and Thealoz Duo® that do not contain preservatives in their composition 
had not cytotoxic effect on the cells. Vismed® Light containing the preservative 
polyhexanide was not toxic, either. It was found that the so-called mild preserva-
tives can also have an adverse effect on the ocular surface. Among the artificial 
tears, the greatest toxic effect on corneal epithelial cells was observed in the tear 
substitutes Ophtolique®, Lacrisifi®, Hypromellose®, Slezin®, and Cationorm® 
containing BAC at various concentrations as preservative and in the artificial tears 
Artelac® Balance (Purite®) and Optive® (Oxide®). The study showed the possibility 
in principle to use in vitro systems for the comparative assessment of the cytotoxic 
effect of tear substitutes. It should be noted, however, that the test system under 
consideration has a number of limitations due to the very nature of the method. 
In particular, studies on cell cultures cannot take into account such aspects that 
are important in terms of general toxicology as the route of delivery of a chemical 
agent into the body, its distribution, elimination, and other toxicodynamics issues. 
Like with the use of other model test systems, extrapolation of the results obtained 
to the whole body requires great caution, especially when it comes to quantitative 
indicators. However, in vitro testing provides information on the potential effects of 
drugs and their specific effects. Given that the problem of drug therapy of patients 
with DES has been recently attracting increasing attention of ophthalmologists 
due to both the increasing prevalence of DES and the increasing range of “artificial 
tear” drugs, screening the cytotoxicity of a wide range of tear substitutes using test 
systems based on cell cultures can promote the rational selection of these drugs.
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